Houston Firm Allocates $150M to Innovative Healthcare Diagnostics

Key Takeaways

Hamershlag Private Capital Management has invested $150.15 million in Patho Care LLC, a leader in noninvasive diagnostics.
The investment will enhance Patho Care’s operational efficiency and expand its service offerings.
The transaction involves the acquisition and recapitalization of Patho Care, facilitating the repayment of its existing financial obligations.

Investment in Innovative Diagnostics

Houston-based Hamershlag Private Capital Management Limited (HPCM) has made a significant investment of $150.15 million in Patho Care LLC, a company renowned for its advancements in medical diagnostics. Patho Care specializes in “lab on a chip” technology, focusing on noninvasive point-of-care testing methods. Their innovative metabolic systems utilize Raman spectroscopy, a technique that allows for fast and accurate detection of current or future respiratory bacterial and viral infections.

The diagnostic devices developed by Patho Care are programmable, mobile, and reusable, positioning them as more efficient and cost-effective alternatives to conventional diagnostic tools. According to L. Mychal Jefferson, Chairman of Hamershlag, this investment aligns strategically with HPCM’s vision of collaborating with high-potential firms within dynamic sectors.

The structure of the investment includes an acquisition and recapitalization of Patho Care LLC, utilizing a mix of newly issued common stock and cash to create PathoCare Holdings Inc. This approach is intended to not only support Patho Care’s growth but also to address its existing financial commitments, ensuring the company is financially stable moving forward.

With this infusion of capital, Patho Care is poised to enhance its operational efficiencies and broaden its portfolio of services, focusing on innovative solutions in the diagnostic testing landscape. Both companies anticipate that this partnership will unlock new growth opportunities while preserving Patho Care’s commitment to excellence and innovation in emergent technologies.

Jefferson emphasized the firm’s dedication to transformational value through innovative investments, expressing strong confidence in Patho Care’s vision and capabilities to redefine healthcare diagnostics. This partnership promises to advance Patho Care’s impact in the medical sector while further solidifying HPCM’s investment strategy in cutting-edge health technology ventures.

The content above is a summary. For more details, see the source article.